Targets from Clinically Broadly Active—or Dirty—Drugs

GPCR (small ligand) Enzyme (small substrate) Ion channel Nuclear receptor Industry 

Enzyme Qarge substrate) GPCR (large ligand) Cytotoxic/other Protein kinase Rate of Success 

The industry has often continued focus on tgst types that have brought rich Ewaids in the past. 

But it is hard to argue against a modest upside being strategically better than a precipitous downside in this risky and very capital-intensive business. 

The concept here is to try and make better drugs from a very effective drug with multiple effects. You do it by dissecting the multiple actions of clinically active drugs. Unfortunately, it is not easy to describe this without continued reference to rather technical concepts. 

---

Targets from Clinically Broadly Active—or Dirty—Drugs... 

---